Clinical Trial Update: Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluating rotational therapy with Imatinib and Nilotinib in Ph+ BCR-ABL+ acute lymphoblastic leukemia (ALL), completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Imatinib (imatinib)
• Nilotinib (nilotinib)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Treatment, Stem Cell Transplantation | Phase 2 | Status: COMPLETED